Actively Recruiting
Aimmune Longitudinal Collaboration Study
Led by Aimmune Therapeutics, Inc. · Updated on 2025-10-20
60
Participants Needed
2
Research Sites
39 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will include healthy households around the Irvine, CA area (based local to employees) and Tempe, AZ and Philadelphia, PA sites that will be instructed to take a daily fiber supplement (2.5 tablespoons of chia seeds \[\~10.3g of fiber\] which is one serving) for two months. Participants will use a stool sampling tool to facilitate ease of stool collection, or they may donate at a study site. Half of participants will add chia seeds to their diet at the beginning of the study and then return to their baseline diet for the second half of the study; half of participants maintain their baseline diet for the first half of the study and add chia seeds to their diet at the second half of the study as a cross-over design. Households (or individual participants, if their household is not participating) will be chosen at random to decide who implements the intervention in the first half versus the second half of the study. Data measurement including metabolomics and sequencing of stool samples, blood sampling for biobanking, stool IgA analysis, stress and diet evaluations will occur initially and throughout the study. Lifestyle questionnaires including but not limited to diet surveys, stress, or depression screening may be collected through electronic forms or telephonically. During enrollment, participants may be asked to complete questionnaires focused on medical, family, dietary, and social histories. At the end of the study, donor microbiota samples from individuals that are IgA low (undetectable) throughout the study will be evaluated from the presence of microbes that can degrade IgA. If investigators find this is the case, investigators will screen for microbes that can degrade IgA. For individuals that show persistent high fecal IgA or show a substantial improvement in IgA, investigators will transplant fecal samples or spores from fecal samples into germ-free mice to further understand the microbiome and pathophysiology relationship. For the latter, the investigator's hypothesis is that fiber exposure of a specific type will reprogram the microbiome to stimulate IgA broadly to the entire microbiome as occurs with pectin derivative treated mice. The investigator's goal will be to isolate the microbes that respond to fiber to alter levels of IgA in the gut lumen.
CONDITIONS
Official Title
Aimmune Longitudinal Collaboration Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or greater
- Able to sign informed consent in English
- Households (2 or more adults) or individuals willing to provide a minimum of 3 stool samples per week and use a manual stool sampling tool or come to a collection site
- Generally healthy
- Agreeable to adding chia seeds to diet
- Have access to a smartphone
You will not qualify if you...
- Less than 18 years of age
- Greater than 50 years of age
- Unable to provide a minimum of 3 stool samples per week
- Active donors for a commercial product
- Previously made a lot of a finished product
- Diagnosed with digestive, intestinal, or other condition contraindicating daily chia seed consumption (~2.5 tbsp)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Aimmune Therapeutics Manufacturing
Ambler, Pennsylvania, United States, 19002
Actively Recruiting
2
GoodNature Tempe
Ambler, Pennsylvania, United States, 19002
Actively Recruiting
Research Team
A
Allison Nelson, NP
CONTACT
N
Nicole Delehanty, DNP
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here